Expression of hypoxia-inducible factor-1α (HIF-1α) in pituitary tumours

Histology and Histopathology

Volumn 18, Issue 3, 2003, Pages 679-686

  Vidal, S ^b,c   Horvath, E ^c   Kovacs, K ^c   Kuroki, T ^a,d   Lloyd, R V ^a   Scheithauer, B W ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d TOHO UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Hypoxia; Hypoxia inducible factor 1 ; Immunohistochemistry; MIB 1; Pituitary tumours

Indexed keywords

BROMOCRIPTINE; CORTICOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LONG ACTING DRUG; OCTREOTIDE; PROLACTIN; SOMATOSTATIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NUCLEOLUS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD; STAINING; STATISTICAL ANALYSIS; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BROMOCRIPTINE; CARCINOMA; CELL DIVISION; CELL NUCLEOLUS; CELL NUCLEUS; CHILD; CYTOPLASM; DOPAMINE AGONISTS; ENDOTHELIUM, VASCULAR; FEMALE; HORMONE ANTAGONISTS; HORMONES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OCTREOTIDE; PITUITARY NEOPLASMS; SOMATOSTATIN; TRANSCRIPTION FACTORS;

EID: 0037789551     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Banerjee S.K., Zoubine M.N., Tran T.M., Weston A.P. and Campbell D.R. (2000). Overexpression of vascular endothelial growth factor 164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells. Int. J. Oncol. 16, 253-260.
2. Berra E., Roux D., Richard D.E. and Pouyssegur J. (2001). Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: Nucleus or cytoplasm. EMBO Rep. 2, 615-620.
3. Bevan J.S., Webster J., Burke C.W. and Scanlon M.F. (1992). Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13, 220-240.
4. Birner P., Gatterbauer B., Oberhuber G., Schindl M., Rossler K., Prodinger A., Budka H. and Hainfellner J.A. (2001). Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer 92, 165-171.
5. Brizel D.M., Dodge R.K., Clough R.W. and Dewhirst M.W. (1999). Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53, 113-117.
6. Brizel D.M., Schroeder T., Scher R.L., Walenta S., Clough R.W., Dewhirst M.W. and Mueller-Klieser W. (2001). Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 51, 349-353.
7. Bunn H.F. and Poyton R.O. (1996). Oxygen sensing and molecular adaptation and hypoxia. Physiol. Rev. 76, 839-885.
8. Cadwell C. and Zambetti G.P. (2001). The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277, 15-30.
9. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E. and Keshet E. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490.
10. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Talks K., Pezzella F., Gatter K.C. and Harris A.L. (2001). Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85, 881-890.
11. Heaney A.P. and Melmed S. (1999). Pituitary tumour transforming gene: A novel factor in pituitary tumour formation. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 13, 367-380.
12. Heaney A.P. and Melmed S. (2000). New pituitary oncogenes. Endocr. Relat. Cancer 7, 3-15.
13. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U. and Vaupel P. (1996b). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509-4515.
14. Hockel M., Schlenger K., Mitze M., Schaffer U. and Vaupel P. (1996a). Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 6, 3-9.
15. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., Gassmann M., Gearhart J.D., Lawler A.M., Yu A.Y. and Semenza G.L. (1998). Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12:149-162.
16. Jugenburg M., Kovacs K., Stefaneanu L. and Scheithauer B.W. (1995). Vasculature in nontumorous hyphophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study. Endocrine Pathol. 6, 115-124.
17. Kalra R., Jones A.M., Kirk J., Adams G.E. and Stratford I.J. (1993). The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast-cancer cells in vitro. Int. J. Cancer 54, 650-655.
18. Kovacs K., Lloyd R., Horvath E., Asa S.L., Stefaneanu L., Killinger D.W. and Smyth H.S. (1989). Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am. J. Pathol. 134, 345-353.
19. Kovacs K., Stefaneanu L., Horvath E., Lloyd R.V., Lancranjan I., Buchfelder M. and Fahlbusch R. (1991). Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch. (A) 418, 439-446.
20. Lloyd R.V., Scheithauer B.W., Kuroki T., Vidal S., Kovacs K. and Stefaneanu L. (1999). Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr. Pathol. 10, 229-235.
21. Lohrer P., Gloddek J., Hopfner U., Losa M., Uhl E., Pagotto U., Stalla G.K. and Renner U. (2001). Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 74, 95-105.
22. Lowe S.W., Ruley H.E., Jacks T. and Housman D.E. (1993a). p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967.
23. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A. and Jacks T. (1993b). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849.
24. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W. and Ratcliffe P.J. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94, 8104-8109.
25. Molitch M.E. (1999). Medical treatment of prolactinomas. Endocrinol. Metab. Clin. North. Am. 28, 143-169.
26. Pluquet O. and Hainaut P. (2001). Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 174, 1-15.
27. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L. and Bedi A. (2000). Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34-44.
28. Rivard A., Berthou-Soulie L., Principe N., Kearney M., Curry C., Branellec D., Semenza G.L. and Isner J.M. (2000). Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J. Biol. Chem. 275, 29643-29647.
29. Sakata K., Kwok T.T., Murphy B.J., Laderoute K.R., Gordon G.R. and Sutherland R.M. (1991). Hypoxia-induced drug resistance: Comparison to P-glycoprotein-associated drug resistance. Br. J. Cancer 64, 809-814.
30. Salceda S. and Caro J. (1997). Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272, 22642-22647.
31. Sanno N., Teramoto A. and Osamura R. (2001). Tyramide amplification in immunohistochemistry. In: Morphology Methods: Cell and Molecular Biology Techniques. Lloyd R.V. (ed). Humana Press. Totowa, New Jersey. pp 267-276.
32. Semenza G.L. (1999). Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15, 551-578.
33. Semenza G.L. (2001a). Hypoxia-inducible factor 1: Control of oxygen homeostasis in health and disease. Pediatr. Res. 49, 614-617.
34. Semenza G.L. (2001b). HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13, 167-171.
35. Semenza G.L., Jiang B.H., Leung S.W., Passantino R., Concordet J.P., Maire P. and Giallongo A. (1996). Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271, 32529-32537.
36. Suhardja A.S., Kovacs K.T. and Rutka J.T. (1999). Molecular pathogenesis of pituitary adenomas: A review. Acta Neurochir. (Wien) 141, 729-736.
37. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. and Harris A.L. (2000). The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157, 411-421.
38. Thapar K., Scheithauer B.W., Kovacs K., Pernicone P.J. and Laws E.R. Jr. (1996). p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 38, 763-770.
39. Turner H.E., Nagy Z., Gatter K.C., Esiri M.M., Harris A.L. and Wass J.A. (2000a). Angiogenesis in pituitary adenomas and the normal pituitary gland. J. Clin. Endocrinol. Metab. 85, 1159-1162.
40. Turner H.E., Nagy Z., Gatter K.C., Esiri M.M., Wass J.A. and Harris A.L. (2000b). Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: Relationship to tumour behaviour. Br. J. Cancer 82, 1441-1445.
41. Turner H.E., Nagy Z., Sullivan N., Esiri M.M. and Wass J.A. (2000c). Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin. Endocrinol. (Oxf) 53, 337-344.
42. Vaupel P., Kelleher D.K. and Hockel M. (2001). Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 28, 29-35.
43. Vidal S., Kovacs K., Cohen S.M., Stefaneanu L., Lloyd R.V. and Scheithauer B.W. (1999). Vascular endothelial growth factor (VEGF) expression in nontumorous human pituitaries. Endocr. Pathol. 10, 109-122.
44. Vidal S., Scheithauer B.W. and Kovacs K. (2000). Vascularity in nontumorous human pituitaries and incidental microadenomas. A morphometric study. Endocrine Pathol. 11, 215-227.
45. Vidal S., Kovacs K., Horvath E., Scheithauer B.W., Kuroki T. and Lloyd R.V. (2001). Microvessel density in pituitary adenomas and carcinomas. Virchows Arch. 438, 595-602.
46. Vidal S., Horvath E., Kovacs K., Lloyd R.V. and Scheithauer B.W. (2003). Microvascular structural entropy: A novel approach to assess angiogenesis in pituitary tumors. Endocr. Pathol. (in press).
47. Wallace-Brodeur R.R. amd Lowe S.W. (1999). Clinical implications of p53 mutations. Cell. Mol. Life Sci. 55, 64-75.
48. Wang G.L. and Semenza G.L. (1995). Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237.
49. Wang G.L., Jiang B.H., Rue E.A. and Semenza G.L. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514.
50. Young S.D., Marshall R.S. and Hill R.P. (1988). Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA 85, 9533-9537.
51. Yu J.L., Rak J.W., Carmeliet P., Nagy A., Kerbel R.S. and Coomber B.L. (2001). Heterogeneous vascular dependence of tumro cell populations. Am. J. Pathol. 158, 1325-1334.
52. Yu R. and Melmed S. (2001). Oncogene activation in pituitary tumors. Brain Pathol. 11, 328-341.
53. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W. and Sementa G.L. (2000). Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 88, 2606-2618.
54. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L. and Simons J.W. (1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59, 5830-5835.